Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for cardiopulmonary diseases, with its current focus on pulmonary arterial hypertension (PAH). Its lead candidate, IKT-001, is an oral prodrug of imatinib designed to reduce gastrointestinal side effects… From the company’s description.
In fiscal 2025, Inhibikase Therapeutics, Inc. reported a net loss of $48.26M. Operations used $27.79M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Inhibikase Therapeutics, Inc. does
In the company’s own words
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for cardiopulmonary diseases, with its current focus on pulmonary arterial hypertension (PAH). Its lead candidate, IKT-001, is an oral prodrug of imatinib designed to reduce gastrointestinal side effects while delivering systemic exposure; the company is evaluating it in the adaptive Phase 3 IMPROVE-PAH study. Inhibikase has global commercialization rights to IKT-001, which is not approved for sale. It also developed risvodetinib for neurodegenerative disease, but paused its development in 2025 and licensed global development, manufacturing and commercialization rights to ABLi Therapeutics. The company began operations in 2008, initially working on protein kinase inhibitors for infectious diseases, later expanding into brain disorders; in 2025 it acquired CorHepta Pharmaceuticals. In 2025, it initiated its Phase 3 PAH program, with sites planned across approximately 180 locations worldwide. Its website is https://www.inhibikase.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- WILMINGTON, DE
- Fiscal year end
- December
- CIK
- 1750149
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Inhibikase Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Inhibikase Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Inhibikase Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Inhibikase Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Inhibikase Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”